- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07794826
Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)
Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.
In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.
It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.
This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Wan-Chuan Tsai, M.D., Ph.D.
- Numer telefonu: 1780 886-289667000
- E-mail: mkks618@gmail.com
Lokalizacje studiów
-
-
Banciao Dist.
-
New Taipei City, Banciao Dist., Tajwan, 220
- Far Eastern Memorial Hospital
-
Kontakt:
- Wan-Chuan Tsai, M.D., Ph.D.
- Numer telefonu: 1780 886-277281780
- E-mail: mkks618@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Diagnosis of Restless Legs Syndrome according to standard criteria.
- Age ≥ 20 years.
- Maintenance high-flux hemodialysis for ≥ 3 months.
- Stable vascular access (AV fistula or AV graft).
- Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
- Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
- Clinically stable condition for the past 4 weeks.
- Able and willing to comply with study protocol
Exclusion Criteria:
- Low-flux HD or temporary catheter use
- Serum albumin < 2.5 g/dL
- Recent hospitalization (within 4 weeks)
- Scheduled kidney transplantation
- Active malignancy or infection
- Pregnancy
- Any condition impairing protocol adherence
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
|
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
|
|
Brak interwencji: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit.
The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from Baseline in International Restless Legs Scale (IRLS) Score
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity).
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Albumin Level
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses sleep quality.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in 5-D Itch Scale Score
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses pruritus severity.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses quality of life.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Kappa Free Light Chains Reduction ratio
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Lambda Free Light Chains Reduction ratio
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Ramy czasowe: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby Układu Nerwowego
- Zaburzenia psychiczne
- Procesy patologiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Przewlekła choroba
- Atrybuty choroby
- Zaburzenia snu i czuwania
- Niewydolność nerek
- Zaburzenia snu, wewnętrzne
- Dyssomnie
- Parasomnie
- Stany patologiczne, oznaki i objawy
- Niewydolność nerek, przewlekła
- Niewydolność nerek, przewlekła
- Syndrom niespokojnych nóg
Inne numery identyfikacyjne badania
- FEMH-IRB-TSAI2025
- FEMH-IIT-2026-01 (Inny numer grantu/finansowania: Far Eastern Memorial Hospital)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Ramy czasowe udostępniania IPD
Kryteria dostępu do udostępniania IPD
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .